APEX AMI
- 8,500 participants
- 5 sites in New Zealand
A Multicentre, Randomised, Double-Blind, Parallel-group, Placebo-controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
APEX AMI
Phase III Cardiology
GLCC Activities
- Project Management
- Regulatory Submissions
- Site Management
- Monitoring